Company Management
Michael Pehl
President and CEO
- More than 20 years experience in Hematology and Oncology
- Most recently President, Hematology & Oncology at Celgene
- Launched multiple blockbuster drugs in oncology including Revlimid, Pomalyst, and Abraxane
- Previously served at Amgen
Brendan P. Delaney
Chief Commercial Officer
- More than 20 years of commercial oncology experience on block-buster brands
- Most recently VP, U.S. Hematology/Oncology Commercial at Celgene
- Previously served at Novartis and Genentech
Usama Malik
Chief Business Officer and Interim CFO
- Responsible for business development, corporate and portfolio strategy, and corporate transformation
- Global VP of Corporate Strategy, Innovation, and Digital Ventures at Pfizer Inc.
- Previously served as senior executive & executive advisor at Novartis, BMS, Lily, Schering, Intarcia, Zoetis, Danaher, Quest Diagnostics, Aetna among others
Dr. Morris Rosenberg
Chief Technology Officer
- Over 28 years of biologics drug development experience
- Most recently, EVP of Development responsible for manufacturing, process development and supply chain management at Seattle Genetics
Dr. Robert Iannone
Head of Research & Development and Chief Medical Officer
- More than 13 years of clinical drug development experience
- Most recently, SVP and Head of Immuno-Oncology at AstraZeneca/MedImmune where he oversaw the development of Imfinzi
- Previously was a leader in the development of Keytruda® at Merck Research Laboratories